Talis Biomedical Corporation

TLIS

US87424L2079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-20 pm EDT			5-day change	1st Jan Change
8.7 ^USD	-3.12%		-1.58%	+16.78%

May. 08	Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 02	North American Morning Briefing : Stocks Seen -2-	DJ

Talis Biomedical Corporation Announces Resignation of Brian Coe as President and Director

August 31, 2021 at 04:10 pm EDT

Talis Biomedical Corporation announced that effective immediately Brian Coe has stepped down as President and Director and will continue to work with the company as an advisor.

Latest news about Talis Biomedical Corporation

Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Talis Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Stock Futures Muted; Nvidia Slips in Offhours Trading	Nov. 22	DJ
Talis Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Talis Biomedical Announces Exploration of Strategic Alternatives	Nov. 13	CI
Talis Biomedical Corporation Announces Resignation of Melissa Gilliam from its Board of Directors, as Member of Nominating and Corporate Governance Committee and as Member and Co-Chairperson of Science, Technology and Clinical Affairs Committee	23-09-01	CI
BTIG Adjusts Talis Biomedical's Price Target to $5 From $5.25, Keeps Sell Rating	23-08-16	MT
Talis Biomedical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Transcript : Talis Biomedical Corporation, Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Talis Biomedical Corporation Announces Resignation of Andrew A. Lukowiak as President and Chief Scientific Officer	23-08-02	CI
Talis Biomedical Corporation Announces New Data Supporting the Development of Its Planned CT/NG/TV and Vinal Infections Panels	23-07-27	CI
Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors	23-05-23	CI
Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Transcript : Talis Biomedical Corporation, Q1 2023 Earnings Call, May 11, 2023	23-05-11
Talis Biomedical Corporation Appoints Kimberly Popovits as Lead Independent Director	23-05-08	CI
Talis Biomedical Corporation Announces Executive Changes	23-04-11	CI
Earnings Flash (TLIS) TALIS BIOMEDICAL CORPORATION Reports Q4 Revenue $0.3M	23-03-22	MT
North American Morning Briefing : Stock Futures -2-	23-03-21	DJ
Talis Biomedical Corporation Announces Resignation of Felix Baker from the Board of Directors	23-03-10	CI
Talis Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Earnings Flash (TLIS) TALIS BIOMEDICAL CORPORATION Posts Q3 Revenue $796,000	22-11-03	MT
Talis Biomedical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-02	CI
Transcript : Talis Biomedical Corporation, Q2 2022 Earnings Call, Aug 02, 2022	22-08-02
Earnings Flash (TLIS) TALIS BIOMEDICAL CORPORATION Posts Q2 Revenue $0.6M	22-08-02	MT

Chart Talis Biomedical Corporation

Duration

Period

More charts

Talis Biomedical Corporation is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. The Company is engaged in developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system consists of compact instrument, single-use test cartridges and software that is designed to support a central cloud database, which work together and are designed to provide central laboratory levels of accuracy and be operated by an untrained user. It is also focused on developing Talis One assay kits for respiratory infections, and infections related to women's health and sexually transmitted infections (STIs). It is also developing influenza A and influenza B tests to be included as part of a respiratory panel with its COVID-19 assay (Respiratory Panel), as well as exploring adding a respiratory syncytial virus (RSV) test.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
TALIS BIOMEDICAL CORPORATION	+16.78%	15.85M
MODERNA, INC.	+41.79%	54.04B
IQVIA HOLDINGS INC.	-0.56%	41.92B
LONZA GROUP AG	+49.62%	41.96B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B
BIO-TECHNE CORPORATION	+6.92%	13B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B
MEDPACE HOLDINGS, INC.	+29.60%	12.28B

Other Biotechnology & Medical Research